Provided by Tiger Trade Technology Pte. Ltd.

Incyte

123.40
-0.9750-0.78%
Volume:264.13K
Turnover:32.43M
Market Cap:25.01B
PE:15.72
High:123.56
Open:122.66
Low:121.61
Close:124.37
52wk High:132.60
52wk Low:81.09
Shares:202.70M
Float Shares:169.82M
Volume Ratio:0.68
T/O Rate:0.16%
Dividend:- -
Dividend Rate:- -
EPS(TTM):7.85
EPS(LYR):6.41
ROE:30.67%
ROA:16.83%
PB:3.94
PE(LYR):19.25

Loading ...

Incyte (INCY) Stock Could Be 31% Stretched Following KRAS Data Buzz

Simply Wall St.
·
Aug 30

US FDA Approves Takeda, Protagonist's Drug for Rare Blood Cancer

Reuters
·
Aug 29

Incyte Corp. Stock Underperforms Friday When Compared to Competitors

Dow Jones
·
Aug 29

Incyte Corp Drops in Volume Surge, Last Down 3.0%

THOMSON REUTERS
·
Aug 29

Incyte Partner Knight Seeks Supplemental Approval for Minjuvi Combination in Brazil

MT Newswires Live
·
Aug 28

Incyte Corp. Stock Underperforms Tuesday When Compared to Competitors Despite Daily Gains

Dow Jones
·
Aug 26

Oruka Therapeutics Names Todd Edwards Chief Commercial Officer

Reuters
·
Aug 25

KDP, Ultragenyx, Incyte, ProQR, Aurinia Trending With Analysts

TIPRANKS
·
Aug 22

Incyte President, Global Head of R&D Pablo J. Cagnoni Sells 10,801 Shares for $1.36 Million

Reuters
·
Aug 21

Pharma Sector Doubles Down on AI Amid Hopes of Slashing Costs, Timelines

Reuters
·
Aug 20

Incyte : Canaccord Genuity Initiates Coverage with Buy Rating; Price Target $152

THOMSON REUTERS
·
Aug 20

Incyte Price Target Maintained with a $150.00/Share by HC Wainwright & Co.

Dow Jones
·
Aug 20

Canaccord Genuity Initiates Incyte at Buy With $152 Price Target

MT Newswires Live
·
Aug 20

Incyte Corp. Stock Underperforms Wednesday When Compared to Competitors Despite Daily Gains

Dow Jones
·
Aug 20

Matt Phipps Maintains Hold Rating on Incyte as Promising Early KRAS G12D PDAC Data Face Durability and Safety Uncertainties

TIPRANKS
·
Aug 20

Incyte ‘734 update likely to be ‘very competitive,’ says RBC Capital

TIPRANKS
·
Aug 19

Incyte Corp. Stock Outperforms Competitors on Strong Trading Day

Dow Jones
·
Aug 18

Incyte is Maintained at Overweight by Piper Sandler

Dow Jones
·
Aug 18

Piper Sandler Adjusts Price Target on Incyte to $130 From $110, Maintains Overweight Rating

MT Newswires Live
·
Aug 17

Incyte : Piper Sandler Raises Target Price to $130 from $110

THOMSON REUTERS
·
Aug 17